Harnessing the power of Imaging Phenomics

At Median, we’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

The fight against disease is a joint effort

While our expertise and resources are unique, we don’t work alone. The fight against disease is a joint effort and the spirit of cooperation is found in everything we do. Whether working in clinical trials or patient care and treatment, we share the same single-minded goal. To defeat the diseases that still touch so many lives.

Pushing the boundaries of imaging technology

At Median we’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

CEO’s message


Fredrik Brag talks about how we’re looking to change the game. To transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike.

Read more

The Imaging Phenomics Company™

Median Technologies is the Imaging Phenomics Company™. Learn about our Lesion Management Solution (LMS) technology and iBiopsy®, our Imaging Biomarker Phenotyping System.

Watch

News

18 July 2017

Median Technologies is awarded the Futur40 prize, an initiative launched by Forbes France

Median Technologies, the Imaging Phenomics Company™, announces that on July 13th 2017, it was awarded the Futur40 Prize by Forbes France. The Futur40 ranking is based on data provided by Morningstar and highlights the 40 Paris-listed companies that have distinguished themselves based on their financial performance and the originality of their model.

22 June 2017

Median Technologies and Medidata Partner to Deliver Differentiated Image Management Services in Clinical Trials

France-based Organization to Tap into Medidata Platform to Accelerate the Development of New Medicines in Oncology. Medidata Medical Imaging™ Analyzes, Captures and Manages Fastest Growing Data Source in Healthcare Industry

31 May 2017

Median Technologies to attend the 2017 ASCO Annual Meeting, June 2-6, 2017, McCormick Place, Chicago, IL, USA

Median Technologies, the Imaging Phenomics Company™, announced today that it will be exhibiting at the 2017 ASCO Annual Meeting, June 2-6 at the McCormick Place, Chicago, IL, USA (exhibition dates: June 3-6).

25 April 2017

Median Technologies is awarded the 2017 Tech 40 Label and joins EnterNext Tech 40 Index.

Tech 40 Index includes top-performing Tech companies listed on the Euronext. The Tech 40 Label denotes Median Technologies as a high potential innovative company among Tech companies, and will enhance its visibility among international investors.

12 April 2017

Median Technologies reports Full Year 2016 Financial Results

+ 64% of revenues and €41.8m in net cash as of Dec. 31, 2016. 2016 was a strategic turning point year, with major operational and business development investments made in anticipation of Median’s growth: Executive team strengthening through major company appointments with significant headcount increases in the US and in France. Development of iBiopsy®, the Median imaging phenotyping platform, is driving the R&D effort and is central in the company positioning strategy for upcoming years.

1/5

Opinion

11 July 2017
Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis

Super Resolution Imaging – For Better Medical Image Analysis If you are fan of science fiction films and you are 40+ like me,…

30 May 2017
Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO

Why Cultural Fit Matters when Selecting an Imaging CRO In the clinical trials process, high quality imaging used as surrogate endpoints significantly improves…

16 May 2017
Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials

Minimizing Variability in Imaging Reads for Clinical trials In oncology, response to treatment is typically assessed by measuring tumor size and growth over…

2 May 2017
Putting patient needs first improves engagement – from recruitment to their last medical image.

Putting patient needs first improves engagement – from recruitment to their last medical image.

Putting patient needs first improves patient engagement in a clinical trial, and delivers a better experience for everyone involved – from recruitment to…

26 April 2017
Making Volumetric Tumor Measurements:  The Nuts and Bolts

Making Volumetric Tumor Measurements: The Nuts and Bolts

Going Beyond RECIST – Part 3 Making Volumetric Tumor Measurements:  The Nuts and Bolts  [Part 3 of our 3 Part series on Going…

1/5
Imaging for patient care

Identifying treatments that work

Imaging biomarkers provide a unique insight into treatment progress at every stage of a disease. In cancer for instance, comprehensive quantitative information plays an invaluable role in defining, tracking and measuring treatment outcomes. Providing clear evidence of what works and what doesn’t.

Read more

Imaging for clinical trials

Advancing treatments of the future

Working with biopharmaceutical companies, and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game; transforming the landscape. We’re capturing the power of big data and unique biomarker imaging technology to create a new world of possibilities for biopharma and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

europe

Median Technologies
Les Deux Arcs, Bât B
1800, route des Crêtes
06560 Valbonne
France

Get in touch

Get in touch





Jobs at Median

United States

Legal address
Median Technologies Inc
C/O Pramex International
1251 Avenue of the Americas
3rd Floor
New York NY 10020

US offices

Median Technologies Inc
300 TradeCenter
Suite 5610
Woburn MA 01801

Cookies help us deliver our services. By using our services, you agree to our use of cookies.